Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 15, Issue 4, Pages 509-517
Publisher
Informa UK Limited
Online
2015-11-12
DOI
10.1586/14760584.2016.1115727
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults
- (2015) Beth D. Kirkpatrick et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
- (2015) Sri Rezeki Hadinegoro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
- (2015) Luis Villar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Virus-specific T lymphocytes home to the skin during natural dengue infection
- (2015) Laura Rivino et al. Science Translational Medicine
- The Human CD8+T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes
- (2014) Daniela Weiskopf et al. JOURNAL OF VIROLOGY
- Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
- (2014) Maria Rosario Capeding et al. LANCET
- T-Cell Immunity to Infection with Dengue Virus in Humans
- (2014) Daniela Weiskopf et al. Frontiers in Immunology
- A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
- (2013) Anna P. Durbin et al. JOURNAL OF INFECTIOUS DISEASES
- Reduced Risk of Disease During Postsecondary Dengue Virus Infections
- (2013) Sandra Olkowski et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds
- (2013) Luis Á. Villar et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA
- (2013) Gustavo H. Dayan et al. VACCINE
- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
- (2012) Arunee Sabchareon et al. LANCET
- Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
- (2011) Anna P. Durbin et al. VACCINE
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
- (2010) Dennis Morrison et al. JOURNAL OF INFECTIOUS DISEASES
- Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City
- (2010) Jorge Poo et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search